Engineered microorganisms are widely used in industrial biotechnology and biopharmaceutical applications, including the ...

We'll know more about the company's medium-term prospects by the end of the year.

In 2026, biotechnology shifted from promise to proof as the first fully AI-designed drug showed positive human trial results, CRISPR therapies expanded into new disease areas, and the FDA enforced ...

CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

In 2026, biotechnology is experiencing a pivotal shift as landmark clinical results, regulatory reforms, and in vivo therapeutic platforms move from concept to practice. Breakthroughs such as the ...

CRISPR gene editing specialist Intellia Therapeutics has announced positive topline results from the global Phase III HAELO ...

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

New CRISPR tool shreds targeted cells instead of editing genes, showing promise for killing diseased cells while sparing ...